Synergistic Apoptotic Effects of Taurolidine and TRAIL on Squamous Carcinoma Cells of the Esophagus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
DFFA Monoclonal Antibody (M05), Degradation of the Chromosomal DNA Into Nucleosomal Clone 3A11 Units
DFFA monoclonal antibody (M05), degradation of the chromosomal DNA into nucleosomal clone 3A11 units. DNA fragmentation factor (DFF) is a heterodimeric protein of 40-kD (DFFB) and 45-kD (DFFA) subunits. Catalog Number: H00001676-M05 DFFA is the substrate for caspase-3 and triggers DNA fragmentation during apoptosis. DFF becomes activated Regulatory Status: For research use only (RUO) when DFFA is cleaved by caspase-3. The cleaved fragments of DFFA dissociate from DFFB, the active Product Description: Mouse monoclonal antibody component of DFF. DFFB has been found to trigger both raised against a partial recombinant DFFA. DNA fragmentation and chromatin condensation during apoptosis. Two alternatively spliced transcript variants Clone Name: 3A11 encoding distinct isoforms have been found for this gene. [provided by RefSeq] Immunogen: DFFA (NP_004392.1, 231 a.a. ~ 331 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Sequence: TSSDVALASHILTALREKQAPELSLSSQDLELVTKEDPK ALAVALNWDIKKTETVQEACERELALRLQQTQSLHSLR SISASKASPPGDLQNPKRARQDPT Host: Mouse Reactivity: Human Applications: ELISA, PLA-Ce, S-ELISA, WB-Re, WB-Tr (See our web site product page for detailed applications information) Protocols: See our web site at http://www.abnova.com/support/protocols.asp or product page for detailed protocols Isotype: IgG2a Kappa Storage Buffer: In 1x PBS, pH 7.4 Storage Instruction: Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Entrez GeneID: 1676 Gene Symbol: DFFA Gene Alias: DFF-45, DFF1, ICAD Gene Summary: Apoptosis is a cell death process that removes toxic and/or useless cells during mammalian development. The apoptotic process is accompanied by shrinkage and fragmentation of the cells and nuclei and Page 1/1 Powered by TCPDF (www.tcpdf.org). -
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide -
DFFB (NM 004402) Human Tagged ORF Clone Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC208266 DFFB (NM_004402) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: DFFB (NM_004402) Human Tagged ORF Clone Tag: Myc-DDK Symbol: DFFB Synonyms: CAD; CPAN; DFF-40; DFF2; DFF40 Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin ORF Nucleotide >RC208266 ORF sequence Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGCTCCAGAAGCCCAAGAGCGTGAAGCTGCGGGCCCTGCGCAGCCCGAGGAAGTTCGGCGTGGCTGGCC GGAGCTGCCAGGAGGTGCTGCGCAAGGGCTGTCTCCGCTTCCAGCTCCCTGAGCGCGGTTCCCGGCTGTG CCTGTACGAGGATGGCACGGAGCTGACGGAAGATTACTTCCCCAGTGTTCCCGACAACGCCGAGCTGGTG CTGCTCACCTTGGGCCAGGCCTGGCAGGGCTATGTGAGCGACATCAGGCGCTTCCTCAGTGCATTTCACG AGCCACAGGTGGGGCTCATCCAGGCCGCCCAGCAGCTGCTGTGTGATGAGCAGGCCCCACAGAGGCAGAG GCTGCTGGCTGACCTCCTGCACAACGTCAGCCAGAACATCGCGGCCGAGACCCGGGCTGAGGACCCGCCG TGGTTTGAAGGCTTGGAGTCCCGATTTCAGAGCAAGTCTGGCTATCTGAGATACAGCTGTGAGAGCCGGA TCCGGAGTTACCTGAGGGAGGTGAGCTCCTACCCCTCCACAGTGGGTGCGGAGGCTCAGGAGGAATTCCT GCGGGTCCTCGGCTCCATGTGCCAGAGGCTCCGGTCCATGCAGTACAATGGCAGCTACTTCGACAGAGGA GCCAAGGGCGGCAGCCGCCTCTGCACACCGGAAGGCTGGTTCTCCTGCCAGGGTCCCTTTGACATGGACA GCTGCTTATCAAGACACTCCATCAACCCCTACAGTAACAGGGAGAGCAGGATCCTCTTCAGCACCTGGAA CCTGGATCACATAATAGAAAAGAAACGCACCATCATTCCTACACTGGTGGAAGCAATTAAGGAACAAGAT GGAAGAGAAGTGGACTGGGAGTATTTTTATGGCCTGCTTTTTACCTCAGAGAACCTAAAACTAGTGCACA -
Minimising Blood Stream Infection: Developing New Materials for Intravascular Catheters
medicines Review Minimising Blood Stream Infection: Developing New Materials for Intravascular Catheters Charnete Casimero , Todd Ruddock, Catherine Hegarty, Robert Barber, Amy Devine and James Davis * School of Engineering, Ulster University, Jordanstown BT37 0QB, Northern Ireland, UK; [email protected] (C.C.); [email protected] (T.R.); [email protected] (C.H.); [email protected] (R.B.); [email protected] (A.D.) * Correspondence: [email protected]; Tel.: +44-(0)289-0366-407 Received: 30 July 2020; Accepted: 24 August 2020; Published: 26 August 2020 Abstract: Catheter related blood stream infection is an ever present hazard for those patients requiring venous access and particularly for those requiring long term medication. The implementation of more rigorous care bundles and greater adherence to aseptic techniques have yielded substantial reductions in infection rates but the latter is still far from acceptable and continues to place a heavy burden on patients and healthcare providers. While advances in engineering design and the arrival of functional materials hold considerable promise for the development of a new generation of catheters, many challenges remain. The aim of this review is to identify the issues that presently impact catheter performance and provide a critical evaluation of the design considerations that are emerging in the pursuit of these new catheter systems. Keywords: intravascular catheter; CRBSI; biofilm; CVC; antimicrobial; antifouling 1. Introduction Intravascular catheters are ubiquitous in contemporary care and it has been estimated that 30–80% of hospital patients will have a peripheral venous catheter (PVC) in place at some point during their stay [1–3]. -
Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened. -
ESCMID Online Lecture Library © by Author
Biofilms : how to handle them? Chrisne IMBERT © by author Université de Poiers - UFR Médecine et Pharmacie Laboratoire EBI UMR CNRS 7267– Poiers – France [email protected] Online Lecture Library Bringing PK and PD in fungal infections into the clinic Nijmegen 4-6 July 2014 Background: 2 opposite life-styles: « planktonic » ou « sessile » ? « Planktonic » « sessile » Passively floang Adherent to a substrate © by author ESCMID Online Lecture Library Biofilm 2 Biofilms are on and in us © by author ESCMID Online Lecture Library Candida spp. can form biofilms on ssues and on almost any medical device!3 Biofilms : single-species or mixed ? Single-species biofilms Vascular catheters, Staphylocoques coagulase neg Prosthec cardiac Staphylococcus aureus valve … Pseudomonas aeruginosa Enterobacteries Candida sp Denture, Tissues : skin, Urinary catheter, vaginal mucosa, Contact lenses… © by author lung… • C. albicans + P. aeruginosa ESCMID •Online A. fumigatus Lecture+ P. aeruginosa Library • C. albicans + Streptoccocus Mixed biofilms • C. albicans + Staphylococcus (S. epidermidis, S. aureus) • C. albicans + Gardnerella vaginalis 4 • Fusarium + free living amoebae C Imbert EBI picture A. fumigatus biofilm Ramage et al., 2011 C. albicans biofilm Douglas, 2003 © by author ESCMID Online Lecture Library Bjarnsholt et al, Nature Reviews Drug Discovery 2013 C. neoformans biofilm (polystyrene) 5 Martinez et al, 2010 Main mechanisms explaining anfungal resistance associated to C. albicans biofilms Decreasing Decreasing role role © by author ESCMID -
ICAD Antibody Cat
ICAD Antibody Cat. No.: 2003 ICAD Antibody Immunofluorescence of ICAD in mouse kidney tissue with ICAD antibody at 5 μg/ml. Immunohistochemistry of ICAD in mouse kidney tissue with ICAD antibody at 5 μg/ml. Green: ICAD antibody (2003) Red: Phylloidin staining Blue: DAPI staining Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Mouse ICAD antibody was raised against a 20 amino acid peptide near the carboxy terminus of mouse ICAD. IMMUNOGEN: The immunogen is located within the last 50 amino acids of ICAD. TESTED APPLICATIONS: ELISA, IF, IHC-P, WB September 28, 2021 1 https://www.prosci-inc.com/icad-antibody-2003.html ICAD antibody can be used for detection of of ICAD by Western blot at 1:1000 dilution. A 45 kDa band can be detected. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 5 μg/mL. APPLICATIONS: Antibody validated: Western Blot in mouse samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested. POSITIVE CONTROL: 1) Cat. No. 1402 - Mouse Lung Tissue Lysate PREDICTED MOLECULAR 45 kDa WEIGHT: Properties PURIFICATION: ICAD Antibody is affinity chromatography purified via peptide column. CLONALITY: Polyclonal ISOTYPE: IgG CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: ICAD Antibody is supplied in PBS containing 0.02% sodium azide. CONCENTRATION: 1 mg/ml ICAD antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. STORAGE CONDITIONS: As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. -
Proteomic Analysis of Ubiquitin Ligase KEAP1 Reveals Associated Proteins That Inhibit NRF2 Ubiquitination
Published OnlineFirst February 4, 2013; DOI: 10.1158/0008-5472.CAN-12-4400 Cancer Molecular and Cellular Pathobiology Research Proteomic Analysis of Ubiquitin Ligase KEAP1 Reveals Associated Proteins That Inhibit NRF2 Ubiquitination Bridgid E. Hast1, Dennis Goldfarb2, Kathleen M. Mulvaney1, Michael A. Hast4, Priscila F. Siesser1, Feng Yan1, D. Neil Hayes3, and Michael B. Major1,2 Abstract Somatic mutations in the KEAP1 ubiquitin ligase or its substrate NRF2 (NFE2L2) commonly occur in human cancer, resulting in constitutive NRF2-mediated transcription of cytoprotective genes. However, many tumors display high NRF2 activity in the absence of mutation, supporting the hypothesis that alternative mechanisms of pathway activation exist. Previously, we and others discovered that via a competitive binding mechanism, the proteins WTX (AMER1), PALB2, and SQSTM1 bind KEAP1 to activate NRF2. Proteomic analysis of the KEAP1 protein interaction network revealed a significant enrichment of associated proteins containing an ETGE amino acid motif, which matches the KEAP1 interaction motif found in NRF2. Like WTX, PALB2, and SQSTM1, we found that the dipeptidyl peptidase 3 (DPP3) protein binds KEAP1 via an "ETGE" motif to displace NRF2, thus inhibiting NRF2 ubiquitination and driving NRF2-dependent transcription. Comparing the spectrum of KEAP1-interacting proteins with the genomic profile of 178 squamous cell lung carcinomas characterized by The Cancer Genome Atlas revealed amplification and mRNA overexpression of the DPP3 gene in tumors with high NRF2 activity but lacking NRF2 stabilizing mutations. We further show that tumor-derived mutations in KEAP1 are hypomorphic with respect to NRF2 inhibition and that DPP3 overexpression in the presence of these mutants further promotes NRF2 activation. -
The Genetics of Bipolar Disorder
Molecular Psychiatry (2008) 13, 742–771 & 2008 Nature Publishing Group All rights reserved 1359-4184/08 $30.00 www.nature.com/mp FEATURE REVIEW The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions A Serretti and L Mandelli Institute of Psychiatry, University of Bologna, Bologna, Italy Bipolar disorder (BP) is a complex disorder caused by a number of liability genes interacting with the environment. In recent years, a large number of linkage and association studies have been conducted producing an extremely large number of findings often not replicated or partially replicated. Further, results from linkage and association studies are not always easily comparable. Unfortunately, at present a comprehensive coverage of available evidence is still lacking. In the present paper, we summarized results obtained from both linkage and association studies in BP. Further, we indicated new potential interesting genes, located in genome ‘hot regions’ for BP and being expressed in the brain. We reviewed published studies on the subject till December 2007. We precisely localized regions where positive linkage has been found, by the NCBI Map viewer (http://www.ncbi.nlm.nih.gov/mapview/); further, we identified genes located in interesting areas and expressed in the brain, by the Entrez gene, Unigene databases (http://www.ncbi.nlm.nih.gov/entrez/) and Human Protein Reference Database (http://www.hprd.org); these genes could be of interest in future investigations. The review of association studies gave interesting results, as a number of genes seem to be definitively involved in BP, such as SLC6A4, TPH2, DRD4, SLC6A3, DAOA, DTNBP1, NRG1, DISC1 and BDNF. -
Produktinformation
Produktinformation Diagnostik & molekulare Diagnostik Laborgeräte & Service Zellkultur & Verbrauchsmaterial Forschungsprodukte & Biochemikalien Weitere Information auf den folgenden Seiten! See the following pages for more information! Lieferung & Zahlungsart Lieferung: frei Haus Bestellung auf Rechnung SZABO-SCANDIC Lieferung: € 10,- HandelsgmbH & Co KG Erstbestellung Vorauskassa Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 Zuschläge F. +43(0)1 489 3961-7 [email protected] • Mindermengenzuschlag www.szabo-scandic.com • Trockeneiszuschlag • Gefahrgutzuschlag linkedin.com/company/szaboscandic • Expressversand facebook.com/szaboscandic DFFA Recombinant Protein (OPCD02721) Data Sheet Product Number OPCD02721 Product Page http://www.avivasysbio.com/dffa-recombinant-protein-opcd02721.html Product Name DFFA Recombinant Protein (OPCD02721) Size 10 ug Gene Symbol DFFA Alias Symbols A330085O09Rik, DFF35, Dff45, DFF-45, DNA fragmentation factor 45 kDa subunit, DNA fragmentation factor subunit alpha, Icad, ICAD, ICAD-L, IC AD-S, Inhibitor of CAD Molecular Weight 31 kDa Product Format Lyophilized Tag N-terminal His Tag Conjugation Unconjugated NCBI Gene Id 13347 Host E.coli Purity > 95% Source Prokaryotic Expressed Recombinant Official Gene Full Name DNA fragmentation factor, alpha subunit Description of Target Inhibitor of the caspase-activated DNase (DFF40). Reconstitution and Storage Reconstitute in PBS or others. Store at 2-8C for one month. Aliquot and store at -80C for 12 months. Avoid repeated freeze/thaw cycles. Additional Information Endotoxin Level: < 1.0 EU per 1 ug (determined by the LAL method) Additional Information Residues: Lys19 - Ser262 Lead Time Domestic: within 1-2 weeks delivery International: 1-3 weeks Formulation Lyophilized in PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. -
Rxoutlook® 1St Quarter 2019
® RxOutlook 1st Quarter 2020 optum.com/optumrx a RxOutlook 1st Quarter 2020 Orphan drugs continue to feature prominently in the drug development pipeline In 1983 the Orphan Drug Act was signed into law. Thirty seven years later, what was initially envisioned as a minor category of drugs has become a major part of the drug development pipeline. The Orphan Drug Act was passed by the United States Congress in 1983 in order to spur drug development for rare conditions with high unmet need. The legislation provided financial incentives to manufacturers if they could demonstrate that the target population for their drug consisted of fewer than 200,000 persons in the United States, or that there was no reasonable expectation that commercial sales would be sufficient to recoup the developmental costs associated with the drug. These “Orphan Drug” approvals have become increasingly common over the last two decades. In 2000, two of the 27 (7%) new drugs approved by the FDA had Orphan Designation, whereas in 2019, 20 of the 48 new drugs (42%) approved by the FDA had Orphan Designation. Since the passage of the Orphan Drug Act, 37 years ago, additional regulations and FDA designations have been implemented in an attempt to further expedite drug development for certain serious and life threatening conditions. Drugs with a Fast Track designation can use Phase 2 clinical trials to support FDA approval. Drugs with Breakthrough Therapy designation can use alternative clinical trial designs instead of the traditional randomized, double-blind, placebo-controlled trial. Additionally, drugs may be approved via the Accelerated Approval pathway using surrogate endpoints in clinical trials rather than clinical outcomes. -
Anti-ICAD Antibody (ARG54401)
Product datasheet [email protected] ARG54401 Package: 50 μg anti-ICAD antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes ICAD Tested Reactivity Hu Tested Application ICC/IF, WB Specificity This antibody recognizes non-cleaved (45kDa) and cleaved DFF45. Host Rabbit Clonality Polyclonal Isotype IgG Target Name ICAD Antigen Species Human Immunogen Peptide corresponding to aa 313-331 at the C-terminus of human DFF45 (accession no. NP_004392). Conjugation Un-conjugated Alternate Names DFF-45; DNA fragmentation factor 45 kDa subunit; Inhibitor of CAD; ICAD; DFF1; DNA fragmentation factor subunit alpha Application Instructions Application table Application Dilution ICC/IF Assay-dependent WB Assay-dependent Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control HeLa, Jurkat, A431 and K562 Calculated Mw 37 kDa Properties Form Liquid Purification Immunoaffinity chroma-tography Buffer PBS (pH 7.4) and 0.02% Sodium azide Preservative 0.02% Sodium azide Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Database links GeneID: 1676 Human Swiss-port # O00273 Human Gene Symbol DFFA Gene Full Name DNA fragmentation factor, 45kDa, alpha polypeptide Background A human DNA fragmentation factor (DFF) which is cleaved by caspase-3 during apoptosis was identified recently.